Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Empresa estonia de biomedicina ofrece una nueva plataforma de inmunoperfilado

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOEE20170330001
Publicado:
02/05/2017
Caducidad:
02/05/2018
Resumen:
Una pyme biomédica de Estonia ha desarrollado una nueva plataforma de inmunoperfilado de alto rendimiento, análisis de variación de mimotopos (MVA), que se emplea en desarrollo de fármacos e identificación de biomarcadores. La plataforma es rentable y permite monitorizar el sistema inmunológico del paciente en tiempo real. La tecnología consiste en el análisis de muestras de péptidos de alto rendimiento y análisis bioinformático. La empresa ofrece la tecnología como servicio y busca socios potenciales interesados en participar en proyectos conjuntos de desarrollo de diagnósticos y medicamentos.

Details

Tittle:
An Estonian biomedical SME is offering a novel immunoprofiling platform
Summary:
An Estonian biomedical SME has developed a novel high-throughput immunoprofiling platform, Mimotope Variation Analysis (MVA), that can be used in drug development and biomarker identification.

MVA is cost-effective and enables monitoring the patient´s immune system in real time. The technology consists of a high-throughput peptide display analysis and of bioinformatic analysis.

The company is looking to provide the MVA technology as a service, and to participate in joint research.
Description:
To reduce increasing healthcare spending and to contribute to healthy ageing it is important to diagnose diseases as early and as accurately as possible. Diseases can be identified early and understood at molecular depth by immunoprofiling, the analysis of peptide-antigen biomarkers.

Although the development of high-throughput technologies can identify a large range of disease biomarkers, the most common technologies still have certain limitations. Current diagnostic tests measure only against a limited number of biomarkers and hence give a limited overview of the patient´s health. Also, the existing analytical platforms and computational tools are not capable of analyzing the large amounts of data necessary to discover immune response related new biomarkers (antigens).

For example, ELISA (enzyme-linked immunosorbent assay) - a rapid test for analysis of antibodies is cost-effective for single biomarker analysis, but not sufficient for general health auditing. Mass-spectrometry assays allow simultaneous analysis of some thousands of biomarkers, however the equipment necessary and running the analyses is costly. Peptide arrays can quantify up to tens of thousands of biomarkers, but similarly the cost per biomarker is very high.

The MVA platform can profile millions of antibodies from a blood sample at a time. It is a cost-effective way to analyse the patient´s immune system in real time. The workflow consists of two main stages:

1. A high-throughput peptide display analysis that is specially designed to query the myriad of antibodies present in a human blood sample.

2. Bioinformatics analysis.

The Estonian SME has also immune-profiled and aggregated data on over 500 billion antibodies and more than 110 million unique ones. This represents the world´s largest antibody biomarker database, which has the potential to decode the human immune system by unlocking information of individualized immune response.

The SME is looking to cooperate with academic and industry partners in the fields of drug development and biomarker discovery. The SME is looking for opportunities to provide MVA technology as a service, and potential partners for joint projects in drug and diagnostics development.
Advantages and Innovations:
Compared to competing technologies, MVA offers cost-effectiveness by combining a vast number of parallel targets in one analysis, and good quantification abilities. The SME makes use of a database involving data on over 500 billion antibodies (more than 110 million unique ones), which constitutes the world´s largest antibody biomarker database.
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
The SME is looking for academic and industry partners working in drug development and biomarker discovery, to:
1) provide MVA as a service;
2) to develop and implement joint projects in drug and diagnostics development.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Estonian
Russian

Keywords

Technology Keywords:
06003001 Bioinformática
06002002 Biología celular y molecular
06001005 Diagnósticos, diagnosis